A study presented at the European Academy of Dermatology and Venereology Congress showed that nearly half of patients with head and neck atopic dermatitis treated with tralokinumab achieved disease clearance after 9 months. The study included 824 adult patients with atopic dermatitis, 655 of which had atopic dermatitis on the head and neck. Results showed that patients experienced significant improvements in their quality of life, with 59% of dupilumab-naïve and 53% of dupilumab-experienced patients reaching IGA 0/1 at 9 months. This study highlights the importance of finding effective treatment options for head and neck atopic dermatitis.
Source link
Tralokinumab shows promise as long-term treatment for head, neck atopic dermatitis
